TradingView chart — Created with TradingView

Disclaimer: The following article provides an in-depth look at the clinical collaboration between Prelude Therapeutics and Merck. This content is for informational purposes only and does not constitute medical advice or commercial promotion of the companies or products mentioned.

Real-time information is available daily at https://stockregion.net

On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The combined treatment will target patients with SMARCA4-mutated cancers, a mutation known to present limited treatment options.

Get 20% off a group subscription

Prelude Therapeutics: Company Background

The clinical trial collaboration and supply agreement between Prelude Therapeutics and Merck outlines the framework for a Phase 2 clinical study. According to the agreement, Merck, known as MSD outside the US and Canada, will provide KEYTRUDA® to Prelude, which will act as the sponsor for the combination trial. Both companies retain all commercial rights to their respective medications, whether used as monotherapies or in combination therapies. Prelude Therapeutics is at the forefront of precision oncology, focusing on developing innovative drug candidates targeting vital cancer cell pathways. The company's pipeline includes several highly differentiated, potentially best-in-class small molecule compounds. Among these are:

PRT3789: A highly selective, first-in-class SMARCA2 degrader.
PRT2527: A potent and highly selective CDK9 inhibitor.
PRT3645: A next-generation CDK4/6 inhibitor.
PRT7732: An orally bioavailable, highly selective SMARCA2 degrader.

These candidates are developed to address clinically validated pathways for cancers affecting specific, underserved patient populations. PRT3789 is designed as a potent and highly selective SMARCA2 degrader. It works by targeting and degrading the SMARCA2 protein, which plays a role in chromatin remodeling and gene expression regulation. The degradation of SMARCA2 can potentially disrupt the survival mechanisms of cancer cells, particularly those with SMARCA4 mutations.

Get 20% off a group subscription

Current Clinical Development

PRT3789 is currently in Phase 1 clinical development, focusing on biomarker-selected patients with SMARCA4 mutations. The objectives of this initial phase are to:

Establish the safety and tolerability profile of PRT3789 as both a monotherapy and in combination with docetaxel.
Evaluate the drug's activity, pharmacokinetics, and pharmacodynamics.
Determine the appropriate dose and potential indications for advancement into registrational clinical trials.

The Phase 1 study is progressing well, with enrollment on track. The company plans to conclude monotherapy dose escalation by mid-2024 and identify the recommended Phase 2 dose. Enrollment of patients into back-fill cohorts enriched for non-small cell lung cancer (NSCLC) and SMARCA4 loss-of-function mutations is ongoing.

The decision to combine PRT3789 with KEYTRUDA® is backed by robust pre-clinical data. At the 2023 AACR International Conference on Molecular Targets and Cancer Therapeutics, Prelude presented findings demonstrating the enhanced anti-tumor immunity achieved by combining SMARCA2 degraders with anti-PD-1 monoclonal antibodies in SMARCA4-mutated cancers. These pre-clinical models showed promising tumor regression, providing a strong foundation for the clinical evaluation of this combination therapy.

Jane Huang, M.D., President and Chief Medical Officer of Prelude Therapeutics, expressed optimism regarding the collaboration with Merck. She highlighted the potential benefits of combining the novel, highly selective SMARCA2 degrader with KEYTRUDA®, an established immunotherapy. This combination could offer new hope for patients with SMARCA4 mutations, who historically have had limited treatment options.

Get 20% off a group subscription

KEYTRUDA®: A Brief Overview

KEYTRUDA® (pembrolizumab) is a well-known anti-PD-1 therapy developed by Merck. It works by blocking the interaction between PD-1 proteins on T cells and PD-L1 proteins on cancer cells, thereby enhancing the body's immune response against tumors. KEYTRUDA® has been approved for various cancer types and is a cornerstone in immuno-oncology treatments.

The upcoming Phase 2 clinical study will primarily focus on evaluating the safety, tolerability, and efficacy of the combination of PRT3789 and KEYTRUDA® in patients with SMARCA4-mutated cancers. Specific objectives include:

Assessing the overall response rate to the combination therapy.
Monitoring progression-free survival and overall survival rates.
Evaluating the pharmacokinetic and pharmacodynamic profiles of PRT3789 when used in combination with KEYTRUDA®.

The study will enroll patients with confirmed SMARCA4 mutations, aiming to provide valuable insights into the potential benefits and risks associated with this innovative combination therapy.

The clinical collaboration between Prelude Therapeutics and Merck signifies major success in the field of precision oncology. By combining PRT3789, a novel SMARCA2 degrader, with KEYTRUDA®, an established anti-PD-1 therapy, the partnership aims to explore new therapeutic possibilities for patients with SMARCA4-mutated cancers. This collaboration underlines the importance of innovative research and clinical trials in advancing cancer treatment and improving patient outcomes.

Share Stock Region Research

Disclaimer: This article is intended for informational purposes only and should not be construed as medical advice or an endorsement of the companies or products mentioned. Always consult with a healthcare professional for medical advice and treatment options tailored to individual needs.

Real-time information is available daily at https://stockregion.net

Stock Region Research

Therapeutics Company Announces Major Clinical…